DEFA14A: Dynavax Defends Strategy Against Deep Track Capital, Highlights Strong Financial Performance and Pipeline Expansion

Dynavax Technologies responds to Deep Track Capital's investor presentation, emphasizing its record financial results, continued momentum, and strategic plan for long-term value creation.

Summary

• Dynavax Technologies Corporation has issued a statement addressing concerns raised by Deep Track Capital regarding the company's strategic direction.
• Dynavax defends its approach, highlighting its strong financial performance and commitment to long-term value creation.
• The company emphasizes its success in growing HEPLISAV-B revenue and strategically investing in both internal and external assets.
• Dynavax reported Q1 2025 total revenue of $68.2 million, a 34% increase compared to Q1 2024.
• HEPLISAV-B net product revenue reached $65 million in Q1 2025, a 36% increase year-over-year, putting Dynavax on track to achieve the top half of its full-year guidance range of $305 to $325 million.
• The company's HEPLISAV-B total estimated U.S. market share increased to approximately 43% in Q1 2025.
• Dynavax expects Adjusted EBITDA to be at least $75 million in 2025.
• Dynavax has executed over 85% of its $200 million share repurchase program as of May 5, 2025.
• The company is advancing its vaccine pipeline, including programs for pandemic influenza and Lyme disease.
• Dynavax urges stockholders to vote for its four director nominees at the upcoming Annual Meeting on June 11, 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Dynavax, highlighting strong financial performance, pipeline expansion, and a defense against activist investor concerns. While there are risks associated with the business, the overall tone is optimistic and confident.

Positives

• Dynavax reported a 34% increase in total revenue for Q1 2025.
• HEPLISAV-B revenue increased by 36% in Q1 2025, indicating strong product growth.
• The company's U.S. market share for HEPLISAV-B has increased to approximately 43%.
• Dynavax is on track to meet its full-year revenue guidance.
• The company expects significant Adjusted EBITDA growth in 2025.
• Dynavax is actively returning capital to stockholders through share repurchases.
• The company is expanding its vaccine pipeline with new programs for pandemic influenza and Lyme disease.
• Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology Select Industry Index's return of -7%.

Negatives

• Adjusted EBITDA was negative $4 million in Q1 2025, although an improvement from negative $7 million in Q1 2024.
• Deep Track Capital is challenging Dynavax's strategic direction, creating potential uncertainty.

Risks

• The company faces risks related to commercializing and supplying HEPLISAV-B.
• Market size or actual demand for Dynavax's products may differ from expectations.
• Clinical trial results may not be favorable.
• Development and testing of vaccines containing CpG 1018 adjuvant carry inherent risks.
• Implementation of long-term growth objectives may face challenges.
• The outcome of the proxy contest with Deep Track Capital could impact the company's strategy.

Future Outlook

Dynavax anticipates continued growth and value creation, driven by HEPLISAV-B and its expanding vaccine pipeline, with a focus on long-term top-line growth and sustained stockholder value.

Management Comments

• Dynavax's strategic plan is working, delivering significant returns to stockholders.
• The company's disciplined capital allocation is the right approach for long-term investors.
• The current Dynavax Board is uniquely equipped to continue successfully advancing Dynavax's strategy.
• The Board and management team remain focused on delivering record results and sustained growth in 2025 and beyond.

Industry Context

Dynavax operates in the competitive biopharmaceutical industry, specifically in the vaccine market. The company's focus on HEPLISAV-B and its proprietary adjuvant technology positions it to compete with established players in the hepatitis B vaccine market and to develop new vaccines for other infectious diseases. The dispute with Deep Track Capital highlights the increasing pressure on biotech companies to deliver short-term returns while also investing in long-term growth.

Comparison to Industry Standards

• Dynavax's strategic pivot in 2019 to prioritize its vaccine business and launch HEPLISAV-B has resulted in a 62% return to stockholders, significantly outperforming the S&P Biotechnology Select Industry Index's return of -7%.
• Compared to vaccine peers, which have returned 9%, Dynavax's 203% stockholder return over the last five years demonstrates superior performance.
• The company's HEPLISAV-B market share of approximately 43% indicates a strong competitive position against established hepatitis B vaccines like Engerix-B and Recombivax HB from GSK and Merck respectively.
• The development of new vaccine programs for pandemic influenza and Lyme disease aligns with industry trends focused on addressing unmet medical needs and emerging infectious disease threats.

Stakeholder Impact

• Shareholders are expected to benefit from the company's continued growth and value creation.
• Employees are likely to be impacted by the company's strategic decisions and pipeline development.
• Customers (healthcare providers and patients) will have access to innovative vaccines.
• Suppliers and creditors will be impacted by the company's financial performance and operational activities.

Next Steps

• Stockholders are urged to vote on the GOLD proxy card for Dynavax's director nominees.
• Dynavax expects to initiate a Phase 1/2 study for its pandemic influenza vaccine program in Q2 2025.
• The company plans to initiate clinical development for its Lyme disease vaccine program in 2027.

Key Dates

Keywords

Dynavax, HEPLISAV-B, vaccine, Deep Track Capital, proxy, stockholder value, revenue, EBITDA, pipeline, share repurchase, pandemic influenza, Lyme disease